Pfizer Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Pfizer Inc (PFE). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|
| Biopharma [Member] | $40.72B 97.8% | $79.56B 97.9% · +95.4% | $99.83B 100.0% · +25.5% | $62.40B 100.0% · -37.5% |
| PC1 [Member] | $926.0M 2.2% | $1.73B 2.1% · +86.9% | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| U.S. [Member] | $21.46B 51.5% | $29.75B 36.6% · +38.6% | $43.32B 42.8% · +45.6% | $28.15B 47.3% · -35.0% | $38.69B 60.8% · +37.5% | $37.08B 59.2% · -4.2% |
| Developed Markets [Member] | – | – | $40.53B 40.1% | $20.91B 35.1% · -48.4% | $16.06B 25.2% · -23.2% | $16.19B 25.9% · +0.8% |
| Emerging Markets [Member] | – | – | $17.32B 17.1% | $10.50B 17.6% · -39.4% | $8.88B 14.0% · -15.4% | $9.31B 14.9% · +4.9% |
| Developed Europe [Member] | $7.79B 18.7% | $18.34B 22.6% · +135.4% | – | – | – | – |
| Developed Rest of World [Member] | $4.04B 9.7% | $12.51B 15.4% · +209.9% | – | – | – | – |
| Emerging Markets [Member] | $8.37B 20.1% | $20.70B 25.5% · +147.3% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.